– Two global Phase 3 trials for maribavir are currently enrolling patients
OSAKA, Japan-Tuesday 24 September 2019 [ AETOS Wire ]
Within three weeks, 62% of patients treated with maribavir, regardless of study dose, saw an effect as result of treatment (400 mg [67%], 800 mg [58%] and 1200 mg [61%]) compared to 56% of those treated with valganciclovir. Treatment effect within six weeks increased to 79% on the maribavir arm (400 mg [79%], 800 mg [83%] and 1200 mg [74%]) versus 67% on the valganciclovir arm.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has
published results of a Phase 2, randomised, 12-week, open-label study
of TAK-620 (maribavir), an investigational, orally bioavailable
antiviral compound being evaluated in patients with cytomegalovirus
(CMV) infection after undergoing hematopoietic cell transplant or solid
organ transplant. CMV is a beta herpes virus that, in patients with
compromised immunity, including organ or stem cell transplant
recipients, causes clinically challenging complications that can be
fatal.1
Maribavir
is designed to target a specific CMV protein, which may lead to
inhibition of CMV DNA replication and encapsidation, and the prevention
of the escape of viral capsids from the nucleus of infected cells. By
inhibiting the CMV UL97 protein kinase, maribavir may potentially affect
several processes in CMV replication including viral DNA synthesis,
viral gene expression, encapsidation and egress of mature capsids from
the nucleus.2
The
Phase 2 study sought to assess the safety and tolerability of maribavir
versus valganciclovir. It was a randomised, 12-week, open-label study
of 159 adults (≥18 years of age) undergoing hematopoietic stem cell
transplant or solid organ transplant with cytomegalovirus reactivation –
evaluated maribavir at 400 mg (n=40), 800 mg (n=40) or 1200 mg (n=39)
twice daily against valganciclovir at 900 mg twice daily for weeks 1-3,
900 mg once daily after week 3 (n=40).
The
primary efficacy endpoint was the proportion of responsive patients
with central laboratory-confirmed undetectable plasma CMV DNA. Sixty-two
percent of patients treated with any dose of maribavir showed a
treatment effect within three weeks of treatment versus 56% with
valganciclovir (risk ratio 1.12; 95% CI, 0.84-1.49). At six weeks,
response rates were 79% and 67% with maribavir and valganciclovir,
respectively (risk ratio 1.20; 95% CI, 0.95-1.51).
The
Phase 2 study showed that maribavir has demonstrated antiviral activity
as a potential treatment of CMV infection and demonstrated a reduction
of actively multiplying CMV in the blood, following hematopoietic cell
transplant or solid organ transplant.
Safety
and tolerability reported in the Phase 2 study found 67% percent of
patients treated with any evaluated dose of maribavir experienced at
least one treatment emergent adverse event (TEAE) that was considered by
the investigators to be related to treatment versus 22% of those
treated with valganciclovir. In the study, most TEAEs with maribavir
(58%) were considered mild to moderate in severity versus 42.5% for
valganciclovir. The most common TEAE with maribavir was dysgeusia, or
altered taste, (40% vs 2% in the valganciclovir group). In line with
earlier reported results, maribavir was associated with an increased
incidence of gastrointestinal adverse events compared with
valganciclovir (20-23% vs. 10-15%). The most frequently reported
treatment emergent serious adverse events (SAE) for those treated with
maribavir were acute graft versus host disease, diarrhea, renal failure
and urinary tract infection with each reported by 3% of treated
patients, versus bacterial sepsis, which was reported in 8% of patients
treated with valganciclovir. Treatment-related SAEs occurred in 10% of
patients treated with maribavir versus 2% of those treated with
valganciclovir.
Treatment
emergent neutropenia was identified in 4% of patients administered
maribavir versus 15% of valganciclovir patients through week six of
treatment and through week 12 neutropenia was seen in 5% of
maribavir-treated patients versus 18% of valganciclovir-treated
patients. Neutropenia occurs when a patient has too few neutrophils, a
type of white blood cell, and is a complication experienced by
transplant patients after their procedure, which can increase the risk
of serious post-transplant complications, including life-threatening
bacterial and fungal infections and, in solid organ transplant patients,
is associated with organ rejection.3 No patients in the maribavir arm discontinued treatment due to myelosuppression or renal impairment.
“There
is a significant unmet need for an additional treatment for
post-transplant patients with CMV infection especially those with a CMV
infection that is resistant to currently available antiviral therapies,”
said Johan Maertens, M.D., Ph.D. of Universitaire Ziekenhuizen Leuven
in Leuven, Belgium, and the trial’s principal investigator and lead
author. “These results are encouraging and warrant further investigation
of maribavir as a potentially effective and tolerated treatment for CMV
in transplant patients.”
Maribavir
has been granted Orphan Drug Designation by the European Commission as a
treatment of CMV disease in patients with impaired cell mediated
immunity and by the U.S. Food and Drug Administration (FDA) for
treatment of clinically significant cytomegalovirus viremia and disease
in at-risk patients. Orphan status is granted to certain investigational
medicines intended for the treatment or prevention of a rare,
life-threatening disease. The FDA has also granted maribavir
Breakthrough Therapy Designation as a treatment for cytomegalovirus
infection and disease in transplant patients resistant or refractory to
prior therapy. Breakthrough Therapy designation expedites the
development and review of investigational treatments for serious
conditions with preliminary clinical evidence indicating that the drug
may demonstrate substantial improvement over available therapy.
Breakthrough Therapy designation does not guarantee that FDA will
approve maribavir for the treatment of CMV infections in transplant
patients, and the timing of any such approval is uncertain.
“Based
on these results, we are evaluating maribavir for the treatment of
post-transplant CMV infection in two global Phase 3 trials,” said Daniel
Curran, M.D., Head of the Rare Diseases Therapeutic Area Unit, at
Takeda. “The continued development of maribavir reflects the progress of
our late-stage rare disease pipeline and our commitment to delivering
innovative medicines for patients who have diseases like CMV where there
are significant unmet needs.”
The
two randomised Phase 3 trials evaluating maribavir for the treatment of
CMV infection in transplant patients are currently enrolling patients.
The first is an open-label superiority study of maribavir 400 mg twice
daily for eight weeks compared to investigator-assigned treatment,
including ganciclovir, valganciclovir, foscarnet or cidofovir, in
hematopoietic cell transplant or solid organ transplant patients with
resistant or refractory CMV infection or disease. The second is a
double-blind non-inferiority study of maribavir 400 mg twice daily for
eight weeks in hematopoietic cell transplant patients experiencing a
first episode of CMV infection.
About the Phase 2 Study
Within three weeks, 62% of patients treated with maribavir, regardless of study dose, saw an effect as result of treatment (400 mg [67%], 800 mg [58%] and 1200 mg [61%]) compared to 56% of those treated with valganciclovir. Treatment effect within six weeks increased to 79% on the maribavir arm (400 mg [79%], 800 mg [83%] and 1200 mg [74%]) versus 67% on the valganciclovir arm.
The
most common TEAE on the maribavir arm was dysgeusia, or an altered
state of taste, which was reported by 40% of those patients compared to
2% of valganciclovir patients. The most frequently reported
treatment-emergent SAEs were acute graft versus host disease, diarrhea,
renal failure and urinary tract infection, each reported by 3% of
maribavir-treated patients. For those treated with valganciclovir, SAEs
of bacterial sepsis were reported by 8% of patients. Adverse events led
to some study drug discontinuation, with maribavir discontinued in 23%
of patients and 12% of valganciclovir patients. The most frequent reason
for discontinuation of maribavir was CMV infection (5%), but there were
no discontinuations due to renal impairment or myelosuppression. The
most frequent cause of discontinuation on the valganciclovir arm was
leukopenia (5%). Dose adjustments due to adverse events occurred in 8%
of maribavir compared to 48% of valganciclovir patients.
Results of the Phase 2 study were first presented at Infectious Disease Week (ID Week) 2016.4
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
Forward-Looking Statements
This
press release and any materials distributed in connection with this
press release may contain forward-looking statements, beliefs or
opinions regarding Takeda’s future business, future position and results
of operations, including estimates, forecasts, targets and plans for
Takeda. In particular, this press release contains forecasts and
management estimates related to the financial and operational
performance of Takeda, including statements regarding forecasts for
Revenue, Operating profit, Adjusted EBITDA, Profit before income taxes,
Net profit attributable to owners of Takeda, Basic earnings per share,
Amortization and impairment and other income/expense, Underlying
Revenue, Underlying Core Earnings margin, Underlying Core EPS and Net
Debt. Without limitation, forward looking statements often include the
words such as “targets”, “plans”, “believes”, “hopes”, “continues”,
“expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could”
“anticipates”, “estimates”, “projects” or words or terms of similar
substance or the negative thereof. Any forward-looking statements in
this document are based on the current assumptions and beliefs of Takeda
in light of the information currently available to it. Such
forward-looking statements do not represent any guarantee by Takeda or
its management of future performance and involve known and unknown
risks, uncertainties and other factors, including but not limited to:
the economic circumstances surrounding Takeda’s business, including
general economic conditions in Japan, the United States and worldwide;
competitive pressures and developments; applicable laws and regulations;
the success of or failure of product development programs; decisions of
regulatory authorities and the timing thereof; changes in exchange
rates; claims or concerns regarding the safety or efficacy of marketed
products or products candidates; and post-merger integration with
acquired companies, any of which may cause Takeda’s actual results,
performance, achievements or financial position to be materially
different from any future results, performance, achievements or
financial position expressed or implied by such forward-looking
statements. For more information on these and other factors which may
affect Takeda’s results, performance, achievements, or financial
position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s
Registration Statement on Form 20-F filed with the U.S. Securities and
Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov.
Neither Takeda nor its management gives any assurances that the
expectations expressed in these forward-looking statements will turn out
to be correct, and actual results, performance or achievements could
materially differ from expectations. Persons receiving this press
release should not place undue reliance on forward looking statements.
Takeda undertakes no obligation to update any of the forward-looking
statements contained in this press release or any other forward-looking
statements it may make. Past performance is not an indicator of future
results and the results of Takeda in this press release may not be
indicative of, and are not an estimate, forecast or projection of
Takeda’s future results.
1 Maertens
J, Cordonnier C, Jaksch P, et.al. Maribavir for Preemptive Treatment of
Cytomegalovirus Reactivation. N Engl J Med 2019;381:1136-47. DOI:
10.1056/NEJMoa1714656.
2 Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19(4):215–229. doi:10.1002/rmv.615
3 Zafrani L, Truffaut L, Kreis H, et.al. Incidence, Risk Factors and Clinical Consequences of Neutropenia Following Kidney Transplantation: A Retrospective Study. Am J Transplant. 2009 Aug;9(8): 1816-25. DOI: 10.1111j. 1600-6143.2009.02699.x. Epub 2009 Jun 16.
4 Maertens J, Cordonnier C, Jaksch P, et.al. Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients. Infectious Disease Week 2016. Abstract #2287.
2 Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19(4):215–229. doi:10.1002/rmv.615
3 Zafrani L, Truffaut L, Kreis H, et.al. Incidence, Risk Factors and Clinical Consequences of Neutropenia Following Kidney Transplantation: A Retrospective Study. Am J Transplant. 2009 Aug;9(8): 1816-25. DOI: 10.1111j. 1600-6143.2009.02699.x. Epub 2009 Jun 16.
4 Maertens J, Cordonnier C, Jaksch P, et.al. Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients. Infectious Disease Week 2016. Abstract #2287.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005143/en/
Contacts
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Media outside Japan
Linda Calandra
linda.calandra1@takeda.com
+1 (617) 301-2092
